Kaiser Permanente Archives - Carey Danis & Lowe

Actos MDL No. 2299 Convened for Status Conference in U.S. District Court in Louisiana

By | Actos, Pharmaceutical litigation, Uncategorized

Actos MDL No. 2299 Convened for Status Conference in U.S. District Court in LouisianaParties involved in the Actos multi-district litigation (MDL) in the U.S. District Court for the Western District of Louisiana met for a Status Conference on January 24, 2013. The MDL is known as in re: Actos (Pioglitazone Products Liability Litigation) MDL No. 11-md-2299, and is being presided over by U.S. District Judge Rebecca F. Doherty.

During the most recent Actos MDL Status Conference, the court reviewed recent Actos filings in federal and state courts as well as any new developments since the Actos MDL’s last Status Conference in December 2012. According to an Actos MDL court document, the parties also discussed the progress of the discovery phase. The next Status Conference is scheduled for February 21, 2013.

Plaintiffs whose cases have been consolidated into the Actos MDL have filed their lawsuits against the manufacturer of Actos claiming that the drug caused serious health complications, including bladder cancer.

In a study conducted by Takeda Pharmaceuticals in collaboration with Kaiser Permanente, data shows an increased risk in the development of bladder cancer in patients who have been using Actos for more than 1 year. At this time, the FDA is reviewing information from the Takeda and Kaiser Permanente ten year study. In Europe, healthcare officials have banned sales of Actos following data released from a French epidemiological study that showed a strong link between the ingestion of Actos and the development of bladder cancer.

In other Actos related news, the manufacturer of Actos has received approval to sell a new diabetes drug in the U.S. According to a Bloomberg News report, the Japanese manufacturer of Actos, Takeda Pharmaceuticals, just received approval from the U.S. Food and Drug Administration (FDA) for a new diabetes medication known generically as alogliptin. Takeda Pharmaceuticals intends to market alogliptin in the U.S. by the brand name of Nesina.

Over a five year period, the FDA rejected the new diabetes medication twice before finally granting it approval this month. Whether this new diabetes drug comes with the risk of developing bladder cancer is still uncertain.

Lawyers at Carey Danis & Lowe are currently evaluating Actos claims. If you or someone you love has taken Actos and has subsequently developed bladder cancer, you may be eligible to receive recompense for your pain, suffering, medical expenses, and lost wages.

For a free legal evaluation about your Actos claim and to learn more about filing an Actos bladder cancer lawsuit, contact an experienced trial lawyer at Carey Danis & Lowe at 800.721.2519 today.

European Medicines Agency’s Takes a Stand on Actos

By | Actos, Pharmaceutical litigation, Uncategorized

Submit Your Claim

[contact-form-7 id=”1660″ title=”mirena”]

European Medicines Agency's Takes a Stand on ActosThe European Medicines Agency made an effort to provide more detail on its conclusion regarding the safety of drugs containing pioglitazone, including the diabetes drug Actos. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded in July 2011 that in patients taking medicines containing pioglitazone, such as Actos, their researchers observed an increased risk in the development of bladder cancer.

Though the European Medicines Agency recognizes the risk for patients to develop bladder cancer, they are still recommending that doctors prescribe drugs such as Actos, and other pioglitazone medications, for the treatment of type 2 diabetes.

Their recommendation does place some patients at an increased risk of developing bladder cancer, and in recognizing the threat of cancer development, the European Medicines Agency has added to their stance on pioglitazone medications that doctors prescribing such drugs must closely monitor their patients for any signs of bladder cancer.

Furthermore, the European Medicines Agency recommended that doctors should use careful discretion in determining when to prescribe drugs such as Actos.

In recognizing the link between Actos and increased risk of bladder cancer, France and Germany have made efforts to halt sales of Actos and other pioglitazone medications.

In the United States, the U.S. Food & Drug Administration is currently analyzing data being collected in a 10 year study conducted by Kaiser Permanente Northern California and Takeda Pharmaceuticals Inc., the manufacturer of Actos. After its review of data from the Kaiser Permanente and Takeda study, the FDA will make a conclusion regarding the safety of Actos and other pioglitazone medications.

Currently, the FDA recommends that Actos not be prescribed to patients who are currently suffering from bladder cancer. Signs of bladder cancer include hematuria, or blood present in urine, painful urination, back and pelvic pain, and a frequent need to urinate. If you are taking Actos and are experiencing any of these bladder cancer symptoms, contact your healthcare provider as soon as possible.

In light of the dangers associated with Actos and other pioglitazone medications, lawyers at Carey Danis & Lowe are currently accepting Actos claims.

If you or someone you love has developed bladder cancer as a result of taking Actos or pioglitazone, understand that you do not have to suffer alone. Our experienced pharmaceutical litigation lawyers work closely with clients to win them much deserved justice and compensation.

Receive a free legal consultation about an Actos lawsuit today by calling a lawyer at Carey Danis & Lowe at 800.721.2519.